Lilly to Acquire Morphic to Improve Outcomes ... - Eli Lilly and …
WEBJul 8, 2024 — Lilly will commence a tender offer to acquire all outstanding shares of Morphic for a purchase price of $57 per share in cash (an aggregate of approximately $3.2 billion) payable at closing. The transaction has been approved …
Lilly Completes Acquisition of Morphic to Improve Outcomes and …
WEBAug 16, 2024 — Lilly's tender offer to acquire all of the issued and outstanding shares of common stock of Morphic (the "Shares"), at a purchase price of $57 per Share, net to the stockholder in cash, without interest thereon and subject to any applicable tax withholding, expired as scheduled at one minute past 11:59 p.m., Eastern time, on Aug. 15, 2024 and ...
Lilly inks $3.2B Morphic buyout to take on Takeda in IBD - Fierce …
WEBJul 8, 2024 — Eli Lilly has agreed to buy Morphic for $3.2 billion, giving the Big Pharma control of an oral, midphase challenger to Takeda’s injectable inflammatory bowel disease blockbuster Entyvio.
Lilly to Acquire Morphic to Improve Outcomes for Patients with ...
WEBJul 8, 2024 — Lilly will commence a tender offer to acquire all outstanding shares of Morphic for a purchase price of $57 per share in cash (an aggregate of approximately $3.2 billion) payable at closing....
Lilly beefs up bowel disease drug portfolio with $3.2 bln Morphic …
WEBJul 8, 2024 — Eli Lilly agreed to buy Morphic Holding for $3.2 billion in cash, the companies said on Monday, beefing up its portfolio of inflammatory bowel disease (IBD) drugs and expanding its footprint...
Eli Lilly to pay $3.2 billion in cash to buy this biotech with an IBD ...
WEBJul 8, 2024 — Shares of Morphic Holding Inc. rocketed Monday, after the biopharmaceutical company announced an agreement to be acquired by Eli Lilly & Co. in a cash deal valued at about $3.2 billion. Lilly...
Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence
WEBJul 9, 2024 — Eli Lilly and Company LLY announced a definitive agreement to acquire Waltham, MA-based small biotech Morphic Therapeutics MORF for approximately $3.2 billion. The acquisition will expand...
Lilly beefs up bowel disease drug portfolio with $3.2 billion Morphic …
WEBJul 8, 2024 — (Reuters) -Eli Lilly agreed to buy Morphic Holding for $3.2 billion in cash, the companies said on Monday, beefing up its portfolio of inflammatory bowel disease (IBD) drugs and expanding its...
Lilly to buy Morphic in $3B bet on inflammation drug
WEBJul 8, 2024 — Eli Lilly plans to spend $3.2 billion acquiring a Massachusetts-based biotechnology company and its experimental pill for inflammatory bowel disease. Announced Monday, the all-cash deal has Lilly buying all the outstanding shares of Morphic Therapeutics for $57 apiece — a nearly 80% premium to …
Eli Lilly Buys Morphic For $3.2 Billion - Forbes
WEBJul 8, 2024 — Eli Lilly will acquire biopharmaceutical firm Morphic Holding in a deal valued at $3.2 billion, both companies announced Monday, a transaction that includes an experimental medication for ...
Skip to content